Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults

NCT04313127 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Sponsor

CanSino Biologics Inc.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]